US EditionPublished • loading... • Updated
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
Ivonescimab plus chemotherapy showed an 80% objective response rate and 100% disease control rate in first-line treatment for advanced triple-negative breast cancer, with no treatment-related deaths.
- Yesterday, Akeso, Inc. presented updated Phase II data on ivonescimab at the ESMO Immuno‑Oncology Congress, London, UK, noting the regimen is on China's CDE/NMPA Breakthrough Therapy Designation list.
- The Phase II clinical study extended follow-up to 22.1 months with 36 patients enrolled and 35 patients in efficacy analysis set as of July 15, 2025.
- Efficacy metrics included ORR 80.0% and DCR 100%, with mDOR 12.2 months and mPFS 15.2 months, across all PD‑L1 subgroups.
- Investigators reported mostly grade 1–2 TRAEs with no TRAE‑related discontinuations or deaths, supporting ivonescimab combined with chemotherapy's favorable safety profile.
- A randomized Phase III HARMONi‑BC1/AK112‑308 trial is ongoing; overall survival data are not yet mature, and Akeso issues forward‑looking statements and risk disclosures.
Insights by Ground AI
59 Articles
59 Articles
journalgazette.net+58 Reposted by 58 other sources
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a…
Coverage Details
Total News Sources59
Leaning Left5Leaning Right4Center19Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 18%
C 68%
14%
Factuality
To view factuality data please Upgrade to Premium
